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Abstract
Background: Subjects with abnormal metabolic conditions had increased risk for cardiovascular disease. We
investigated the role of abnormal metabolic conditions on arterial stiffness in healthy subjects with no drug
treatment.
Methods: A total 601 subjects (age 48.7 ± 11.8 years, male 46.2 %, hypertension 19.1 %) were enrolled. Major
cardiovascular risk factors, metabolic conditions and parameters (pre-diabetes, diabetes mellitus, metabolic
syndrome, fasting blood sugar (FBS), glycated hemoglobin), lipid profiles, hsCRP, and brachial ankle pulse wave
velocity (baPWV) were measured.
Results: Subjects with metabolic syndrome (n = 200) had higher baPWV than in subjects without metabolic syndrome
(n = 401) even after adjustments for age, sex and presence of hypertension (1435.9 ± 212.2 vs. 1336.5 ± 225.0 cm/sec,
p < 0.001). The differences of baPWV among normal FBS, prediabetes and diabetes mellitus groups are significant
(P for trend = 0.036) by multivariate analysis (adjustments for age, sex, office systolic blood pressure). Subjects
with diabetes mellitus (n = 30) had higher baPWV than in subjects with normal FBS (n = 384, 1525 ± 267.1 vs.
1341.5 ± 224.1 cm/sec, P = 0.016 adjustments for age, sex, office systolic blood pressure). BaPWV in subjects with
prediabetes (n = 187) was slightly higher, but not statistically significant than in subjects with normal FBS (P = 0.377). Of
interest, FBS was one of the independent predictors for increased baPWV (β = 0.809, 95 % CI 0.222-1.397, p = 0.007) by
multivariate analysis.
Conclusions: Subjects with abnormal metabolic conditions have increased arterial stiffness independent of age and BP
which may contribute to the development of cardiovascular disease.
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Background
Pulse wave velocity (PWV), a marker of arterial stiffness,
has been shown to be an independent predictor of future
cardiovascular events in patients with hypertension,
chronic kidney disease, coronary artery disease and even
in the aged and the community [1–8]. In this regard,
European Society of Hypertension/European Society of
Cardiology guideline for the management of arterial
hypertension recommended arterial stiffness as one of
the markers for asymptomatic organ damages which can
change treatment modality in hypertensive patients [9] .
Metabolic syndrome, a concurrence of disturbed glu-
cose and insulin metabolism, overweight and abdominal
fat distribution, dyslipidemia, and hypertension, is asso-
ciated with subsequent development of type 2 diabetes
mellitus and cardiovascular disease [10]. In addition,
subjects with metabolic syndrome had increased rates of
cardiovascular events and all-cause mortality [11].
In general, PWV is strongly associated with age and
blood pressure (BP). However, findings with regard to its
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relation with other risk factors have been inconsistent
and weak relation with abnormal metabolic conditions
[12–17].
Because, there are still limited data for the relation
between abnormal metabolic conditions and arterial
stiffness and independent role of abnormal metabolic
conditions on arterial stiffness, we investigate the role
of abnormal metabolic conditions on arterial stiffness
in healthy subjects with no drug treatment.
Methods
Subjects and study design
Subjects who visited for cardiovascular health examin-
ation in cardiovascular clinic were enrolled. Some of
study subjects diagnosed as hypertension, diabetes melli-
tus and dyslipidemia. We only enrolled subjects who did
not take any medications within 2 weeks of laboratory
and hemodynamic measurements for more exact diag-
nosis of the presence of hypertension, diabetes mellitus,
dyslipidemia or due to not known the presence of these
conditions at visiting clinic.
The exclusion criteria for this study were subjects
who already diagnosed as cardiovascular disease such
as coronary artery disease, congestive heart failure, stroke,
peripheral artery disease and established renal disease
(serum creatinine >1.4 mg/dL), any liver disease (aspartate
aminotransferase or alanine aminotransferase ≥ 3 times
the upper limit of the normal in our laboratory).
Subjects were measured anthropometric data, major
cardiovascular risk factors, metabolic conditions and
parameters, lipid profiles, high sensitivity (hs) CRP and
blood pressure (BP), heart rate and brachial ankle pulse
wave velocity (baPWV). The study protocol was approved
and written informed consents were waived by the local
ethics committee.
Measurements of blood pressure, heart rate and
anthropometric data
Weight, height, waist and hip circumferences were
measured and body mass index was calculated. Waist
circumference was measured at the level of the iliac
crest. Body mass index was calculated as body weight
in kilograms divided by the square of height in meters
(kg/m2). Patients underwent measurements for BP,
heart rate. Before the BP measurement, patients were
prohibited taking caffeine, smoking or exercise within
30 minutes. Office BP was measured from the right
arm in the sitting position using automated sphygmo-
manometer (TM-2655P, A&D Co. Ltd., Tokyo, Japan)
after at least 10 minutes of seated rest. Three measure-
ments were taken 5 minutes apart and the mean of the
last 2 values was calculated.
Cardiovascular risk factors, lipids, metabolic conditions
and parameters
Diabetes mellitus was defined as fasting glucose ≥126 mg/
dL or 2 hour postprandial glucose ≥ 200 mg/dl or glycated
hemoglobin (HbA1c) ≥6.5 %, or if they were already being
diagnosed for this condition. Pre-diabetes was defined as
fasting glucose (100 ≤ and < 126 mg/dL) or HbA1c (5.7 ≤
and <6.5). According to the revised NCEP criteria [18], an
individual may be diagnosed as having metabolic syn-
drome if he or she has three or more of the following
criteria: 1) waist circumference >90 cm in men and >80 cm
in women using the International Obesity Task Force
criteria for the Asian-Pacific population to determine
waist circumference [19]; 2) triglycerides ≥150 mg/dL
or medication use; 3) HDL cholesterol <40 mg/dL in
men and <50 mg/dL in women or medication use; 4)
blood pressure ≥130/85 mmHg or already being diagnosed
as hypertension; and 5) fasting glucose ≥100 mg/dL or
already being diagnosed as diabetes mellitus.
Hypertension was defined as systolic BP ≥ 140 mmHg
or diastolic BP ≥ 90 mmHg, or if they were already being
diagnosed for this condition. Blood samples for labora-
tory assays were obtained following overnight fasting at
least 8 hours. Total cholesterol and triglycerides were
analyzed with enzymatic methods (Shinyang Chemical,
Seoul, Korea), high density lipoprotein (HDL) choles-
terol by a direct immunoinhibition method (Wako Pure
Chemical, Osaka, Japan). LDL cholesterol was calculated
using the Friedewald equation [20]. Fasting blood sugar
(FBS) was determined by the hexokinase method (Shinyang
Chemical, Seoul, Korea) using a Hitachi 7600–110. Assays
for glycated hemoglobin (HgA1c) were measured by high
performance liquid chromatography assay (VARIANT II
TUR BO®, BIORAD, Inc, Hercules, California). HsCRP
levels were determined with a turbidimetic assay (Denka
Seiken, Tokyo, Japan) using the Hitachi 7600–110. History
of smoking was obtained from all subjects.
Measurement of brachial ankle pulse wave velocity
(baPWV)
The baPWV and supine BP were measured by the auto-
matic wave form analyzer (VP-2000, Nippon Colin Ltd,
Komaki City, Japan) with simultaneous recordings of bi-
lateral brachial and ankle BP, electrocardiogram and
heart sound in a supine position after at least 5-min rest.
One trained observer who did not know subject’s infor-
mation performed all the measurements. The baPWV
was calculated from the equation: (D1 - D2)/T. D1 is the
distance between the suprasternal notch and the ankle,
D2 is the distance between the suprasternal notch and
the brachium, and T is the time interval between the
brachium and ankle. The distances between the sam-
pling points of baPWV are automatically calculated from
the patient’s height. Pearson’s correlation coefficients of
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intra- and inter-observer reproducibility of baPWV were
0.976 and 0.912, respectively, as described elsewhere [21].
Statistical analysis
Continuous variables were expressed as mean ± SD or
median (25 percentile-75 percentile) and categorical
variables were expressed as percentages and frequencies.
Correlations between the levels of baPWV and anthropo-
metric data, blood pressure, heart rate, laboratory data in-
cluding metabolic parameters were tested using Pearson’s
coefficient of correlation. To adjust the influence of age,
sex, presence of hypertension or office systolic BP for
baPWV, the differences of baPWV between subjects with
metabolic syndrome and without metabolic syndrome
and among the normal, pre-diabetes and diabetes mellitus
groups were analyzed by multivariate linear regression
analysis.
To determine the independent predictors for the level
of baPWV, multivariate linear regression analysis was
performed. All possible variables were included for this
analysis if its P value of correlation co-efficiency with
baPWV below 0.2. Values of p < 0.05 were considered
significant. All tests were 2-sided.
Results
Study subjects and baseline characteristics
A total 601 subjects (age 48.7 ± 11.8, male 46.2 %) were
enrolled. The baseline clinical characteristics are sum-
marized in Table 1.
The number of subjects with hypertension was 115
(19.1 %), metabolic syndrome 200 (33.3 %). The number
of subjects with normal fasting blood sugar was 384
(63.9 %), with pre-diabetes 187 (31.1 %), and with diabetes
mellitus 30 (5.0 %).
Correlations between baPWV and anthropometric data,
lipids, metabolic parameters
The correlations between baPWV and anthropometric
data, lipids, metabolic parameters are shown in Table 2.
BaPWV are significantly correlated with age, systolic and
diastolic BP. Of interest, baPWV had significant positive
correlations with waist circumference, total cholesterol,
triglyceride, FBS, HbA1c, creatinine and negative corre-
lations with hip circumference, HDL-cholesterol.
Comparison of baPWV between subjects with metabolic
syndrome and without metabolic syndrome
Subjects with metabolic syndrome had significant higher
baPWV than in subjects without metabolic syndrome
after adjustments of age, sex, presence of hypertension
by multivariate linear regression analysis (1435.9 ± 212.2
vs. 1336.5 ± 225.0 cm/sec, p = 0.001, Fig. 1).
Table 1 Baseline characteristics of study subjects
Variables Data
Age (years) 48.7 ± 11.8
Male (%) 278 (46.2)
Hypertension (%) 115 (19.1)
Pre-diabetes (%) 187 (31.1)
Diabetes mellitus (%) 30 (5)
Office systolic BP (mmHg) 129.3 ± 20.6
Office diastolic BP (mmHg) 79.0 ± 12.7
Office HR (rate) 81.0 ± 30.9
Height (cm) 163.1 ± 10.8
Weight (Kg) 65.3 ± 12.5
waist circumference (cm) 86.6 ± 9.1
hip circumference (cm) 97.0 ± 6.9
Total cholesterol (mg/dL) 203.2 ± 37.6
Triglyceride (mg/dL) 135.6 ± 4.7
HDL cholesterol (mg/dL) 52.3 ± 13.3
LDL cholesterol (mg/dL) 123.7 ± 33.7
FBS (mg/dL) 99.6 ± 22.3
HbA1c (%) 5.78 ± 0.71
hsCRP (mg/L) 0.7 (0.03-1.4)
Data are expressed as mean ± standard deviation or number (percent) or
median (25 percentile −75 percentile)
BP blood pressure, HR heart rate, HDL high density lipoprotein, LDL low
density lipoprotein, FBS fasting blood sugar, HbA1c glycated hemoglocinA1c,
hsCRP high sensitivity C reactive protein




Office systolic BP 0.426 <0.001
Office diastolic BP 0.424 <0.001
Office HR 0.048 0.241
Height −0.68 0.094
Weight −0.042 0.307
Waist circumference 0.132 0.002
Hip circumference −0.086 0.040
Total cholesterol 0.112 0.006
Triglyceride 0.219 <0.001
HDL cholesterol −0.097 0.017





baPWV brachial ankle pulse wave velocity, BP blood pressure, HR heart rate,
HDL high density lipoprotein, LDL low density lipoprotein, FBS fasting blood
sugar, HbA1c glycated hemoglocinA1c, hsCRP high sensitivity C reactive protein
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Comparisons of baPWV among normal FBS, pre-diabetes
and diabetes mellitus groups
The differences of baPWV among three groups are
significant (P for trend = 0.036) by multivariate linear
regression analysis (adjustments for age, sex, office
SBP, Fig. 2). Subjects with diabetes mellitus had higher
baPWV than in subjects with normal FBS (1525.2 ±
267.1 vs. 1341.5 ± 224.1 cm/sec, P = 0.016). BaPWV in
subjects with pre-diabetes is slightly higher (1402.4 ±
207.4 cm/sec), but not statistically significant than in
subjects with normal FBS (P = 0.377).
Independent factors for baPWV
The results of multivariate linear regression analysis of
independent factors for baPWV are shown in Table 3.
As we expected, old age and systolic, diastolic BP were
significant independent predictors for increased baPWV.
In addition, male sex and hip circumference were inde-
pendent factors for baPWV. Of interest, greater FBS was
one of the independent predictors for increased baPWV
(b = 0.809, 95 % CI [0.222-1.397], p = 0.007).
Discussion
Our study revealed that abnormal metabolic conditions
such as metabolic syndrome and diabetes mellitus had
increased arterial stiffness in healthy subjects with no
drug treatment even after adjustments of age, sex and
blood pressure. In addition, increase FBS was independ-
ent predictor for the increased arterial stiffness in the
multivariate analysis. Our study demonstrated that abnor-
mal metabolic conditions increased arterial stiffness which
is one of the risk factors for cardiovascular disease.
Metabolic syndrome is associated with subsequent de-
velopment of type 2 diabetes mellitus and cardiovascular
disease [10]. In addition, subjects with metabolic syndrome
had increased cardiovascular events and all-cause mortality














No Metabolic syndrome Metabolic syndrome
(N=401)                     (N=200)
Fig. 1 The comparison of baPWV between subjects with metabolic
syndrome and without metabolic syndrome. Subjects with metabolic
syndrome had significant higher baPWV than in subjects without
metabolic syndrome after adjustments of age, sex, presence of
hypertension by multivariate linear regression analysis. Data
are presented as mean ± standard deviation of the mean.
















Normal FBS            Pre-diabetes       Diabetes mellitus
(N=384)                   (N=187)                    (N=30)
Fig. 2 The comparisons of baPWV among normal fasting blood sugar, pre-diabetes and diabetes mellitus groups. The differences of baPWV
among three groups are significant (P for trend = 0.036) by multivariate linear regression analysis (adjustments for age, sex, office SBP). Subjects
with diabetes mellitus had higher baPWV than in subjects with normal FBS (P = 0.016). BaPWV in subjects with pre-diabetes is slightly higher,
but not statistically significant than in subjects with normal FBS (P = 0.377). Data are presented as mean ± standard deviation of the mean.
baPWV = brachial ankle pulse wave velocity. FBS = fasting blood sugar. SBP = systolic blood pressure
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syndrome are partly explained by consequence of in-
sulin resistance and abnormal endothelial function
[22–25], there are still limited data on the mechanisms
of poor outcomes in subjects with metabolic syndrome
for cardiovascular disease. In current out study, abnor-
mal metabolic conditions such as metabolic syndrome
and diabetes mellitus had greater arterial stiffness than
in subjects with healthy metabolic state, these results
suggest that increased arterial stiffness in subjects with
abnormal metabolic conditions is one of the mechanisms
for the poor cardiovascular outcomes in subjects with
abnormal metabolic conditions.
Previous some studies reported that abnormal meta-
bolic conditions were related with increased arterial stiff-
ness [12–16, 26], however, there are still controversy for
this topic, especially in subjects without cardiovascular
disease and with no drug treatment. In one small study
using MRI demonstrated that carotid pulse wave velocity
was increased in middle aged subjects with metabolic
syndrome, however, these results did not show in elderly
subjects [26]. In large study including total 8599 subjects
who underwent health examination in South China,
baPWV were positively correlated with metabolic syn-
drome and its individual components. In this study, BP
and FBS had the strongest correlation factors [14]. In
another study, high BP and elevated FBS were associated
with increased baPWV in patients underwent voluntary
healthy checkup [16]. The results of these studies are
consistent with current our study. In patients with meta-
bolic syndrome, one rural community cohort of Korea,
the ARIRANG study, revealed that arterial PWV did not
show significant increase in patients with metabolic syn-
drome, especially in male [13]. In subjects without clin-
ical atherosclerotic cardiovascular disease, diabetes, or
systemic disease, subjects with metabolic syndrome was
associated with an increased baPWV, however, none of
the components of the metabolic syndrome, except for
an elevated BP, was an independent factor for baPWV
[27]. These results suggest that there are still needs for
further investigations regarding the relationships between
metabolic conditions and arterial stiffness.
In current our study, FBS is one of the independent
predictors of increased arterial stiffness by multivariate
analysis. In addition, our study demonstrate that abnormal
metabolic conditions such as metabolic syndrome and
diabetes mellitus had increased arterial stiffness even
after adjustments of age, sex and blood pressure in
healthy subjects with no drug treatment. Our results
suggest that abnormal metabolic parameters or condi-
tions are one of the mechanisms for increased arterial
stiffness independent of age and blood pressure.
The role of hip circumference on arterial stiffness is
not consistent in previous studies [28, 29]. Our study
showed larger hip circumference had protective role for
increased aortic stiffness.
Current our study had some limitations. Enrolled
subjects were visited in cardiovascular department to
check up their cardiovascular health. Therefore, the
generalization of our results should be taken with caution
and selection bias could exist. Second, we used baPWV
instead of carotid-femoral PWV (cfPWV) to assess arterial
stiffness [12]. Although cfPWV is considered the gold
standard for the measurement of arterial stiffness in
Western countries [30] no single methodology is proven to
be superior. Regarding for efficacy for baPWV, Tanaka
et al.[31] reported that the cfPWV and baPWV indices of
arterial stiffness are similarly associated with cardiovascular
risk factors and clinical events. Third, single measurements
of variables including metabolic conditions and parameters
may not represent the exact measurements of subjects’ con-
ditions. Forth, we did not evaluate the clinical outcomes of
study subjects. Further studies regarding the prognostic role
of increased arterial stiffness related with abnormal
metabolic conditions on cardiovascular outcomes will
be required in the future.
Conclusions
Subjects with abnormal metabolic conditions have in-
creased arterial stiffness independent of age and BP
which may contribute to the development of cardiovas-
cular disease. In addition, increased FBS was one of the
independent predictors of increased arterial stiffness.
Our results suggest that treatments for abnormal meta-
bolic conditions including lifestyle modification, drug
treatments may improve arterial stiffness, which can
improve subject’s cardiovascular outcomes.
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Table 3 Independent factors for baPWV by multivariate linear
regression analysis
β 95 % CI P
Age 9.696 8.513, 10.880 <0.001
Male 63.194 34.598, 91.790 <0.001
Office Systolic BP 2.771 1.558, 3.983 <0.001
Office diastolic BP 4.476 2.480, 6.472 <0.001
Hip circumference −4.930 −6.971, −2.888 <0.001
FBS 0.809 0.222, 1.397 0.007
baPWV brachial ankle pulse wave velocity, BP blood pressure, FBS fasting
blood sugar
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